Sativa Investments Share Placing

By in
263

Press Release                                                                                                                                                  18 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Share Placing

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is pleased to announce that it has raised £3.75 million (before expenses) by way of a placing of 62,500,000 new ordinary shares of 0.25p each in the Company (“Ordinary Shares”), at a price of 6 pence per share, to current and new shareholders in the Company. The new shareholders comprise institutions, family offices and private individuals.  Trading in the new Ordinary Shares on the NEX Exchange Growth Market is expected to commence on Monday, 22 October 2018.

The proceeds of the placing will be used to further Sativa’s progress and development as the UK’s first medicinal cannabis investment vehicle. 

Following this issue of new Ordinary Shares, Sativa Investments has 509,900,000 Ordinary Shares in issue, each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury.  The total number of voting rights in the Company is therefore 509,900,000.

The figure of 509,900,000 Ordinary Shares should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

54321
(0 votes. Average 0 of 5)
Leave a reply

Your email address will not be published. Required fields are marked *